Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Phoenix, Arizona

This page shows live ClinicalTrials.gov search results for Phoenix, Arizona, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
8158
Shown on this page
12
Current sort
Recently updated
Location scope
Phoenix, AZ
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Phoenix, Arizona. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 877–888 of 8,158 matching trials in Phoenix, AZ.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Phoenix

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Phase 2 Interventional

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

NCT06848348
View directory record Official record
Conditions
Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain
Interventions
Halneuron, Placebo, Halneuron (Open Label Extension)
Drug
Lead sponsor
Dogwood Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
25
States / cities
Sheffield, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Recruiting Phase 3 Interventional

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT07743463
View directory record Official record
Conditions
Obesity, Overweight, Chronic Weight Management
Interventions
ASC30 tablets A1, Placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years and older
Enrollment
3,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Recruiting Phase 3 Interventional

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

NCT07743450
View directory record Official record
Conditions
Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
Interventions
ASC30 tablets A1, Placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years and older
Enrollment
1,560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
84
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

NCT06602024
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Fluarix®, Influsplit® Tetra, Fluarix Tetra, Alpharix® Tetra
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years and older
Enrollment
40,805 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
188
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 150 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

NCT07023731
View directory record Official record
Conditions
KRAS G12D Mutation, Advanced Solid Cancer
Interventions
ARV-806
Drug
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

NCT06427941
View directory record Official record
Conditions
Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
Interventions
BGB-B2033, Tislelizumab, Bevacizumab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Goodyear, Arizona • Duarte, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

NCT00920972
View directory record Official record
Conditions
Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
Interventions
Treatment Plan 1: Stratum 1, Treatment Plan 2: Strata 2, 3, or 4, GVHD Regimen A: UCB Recipients, GVHD Regimen B: BM Recipients
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 20 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2031
U.S. locations
25
States / cities
Phoenix, Arizona • Orange, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Recruiting Phase 3 Interventional

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

NCT06585410
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions
Cemiplimab, Standard of care
Drug · Procedure
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
48
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Not yet recruiting Early Phase 1 Interventional

A Study of NST-628 in Recurrent Grade 4 Glioma

NCT07784985
View directory record Official record
Conditions
Glioma, Recurrent High Grade, Grade 4 Malignant Glioma
Interventions
NST-628
Drug
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Active, not recruiting Not applicable Interventional

Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer

NCT03697148
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Multiparametric Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
44
States / cities
Phoenix, Arizona • Scottsdale, Arizona • New Haven, Connecticut + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Recruiting No phase listed Observational

Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment

NCT06033274
View directory record Official record
Conditions
Tricuspid Regurgitation
Interventions
Transcatheter Tricuspid Valve Replacement
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Phoenix, Arizona • Wichita, Kansas • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

NCT06045221
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Orforglipron, Semaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
64
States / cities
Phoenix, Arizona • Canoga Park, California • Escondido, California + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 30, 2026, 9:02 PM EDT